Cargando…

Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study

AIM OF THE STUDY: Data regarding hepatocellular carcinoma (HCC) recurrence after directly acting antivirals for hepatitis C are contradictory. Our aim was to study the HCC recurrence in patients who received directly acting antivirals after tumor ablation. MATERIAL AND METHODS: This retrospective st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamal, Ahmed, Elmoety, Amr Aly Abd, Rostom, Yousri Abdelmeguid, Shater, Mohamed Said, Lashen, Sameh Aldesoky
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122091/ https://www.ncbi.nlm.nih.gov/pubmed/34027117 http://dx.doi.org/10.5114/ceh.2021.104397

Ejemplares similares

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals
por: Syed, Taseen, et al.
Publicado: (2018)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma
por: Ismail, Mohamed Saleh, et al.
Publicado: (2020)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
por: Kishta, Sara, et al.
Publicado: (2020)

Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis
por: Lui, Felix H., et al.
Publicado: (2020)

Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
por: Ahn, Young-Hwan, et al.
Publicado: (2021)

Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
por: Ahn, Young-Hwan, et al.
Publicado: (2022)

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2023)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
por: Frazzoni, Leonardo, et al.
Publicado: (2021)

Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer
por: Kuromatsu, Ryoko, et al.
Publicado: (2022)

Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2021)

Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?
por: Butt, Amna Subhan, et al.
Publicado: (2018)

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
por: Lynch, Erica Nicola, et al.
Publicado: (2023)

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
por: Schietroma, Ivan, et al.
Publicado: (2018)

The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017)

Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma
por: Kamp, William M., et al.
Publicado: (2019)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
por: Tse, Chung Sang, et al.
Publicado: (2020)

Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals
por: Fukumoto, Tsuyoshi, et al.
Publicado: (2022)

Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment
por: Imai, Kenji, et al.
Publicado: (2020)

Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma
por: Teng, Wei, et al.
Publicado: (2019)

Frequency of De Novo Hepatocellular Carcinoma after Direct-acting Antiviral Therapy for Chronic Hepatitis C: A Prospective Follow-up
por: Rasool, Shahid, et al.
Publicado: (2022)

Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment – preliminary report
por: Warzyszyńska, Karola, et al.
Publicado: (2017)

Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals
por: Alswat, Khalid, et al.
Publicado: (2022)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal, Sanaa M
Publicado: (2014)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Ramadan, Mohammad Said, et al.
Publicado: (2022)

The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma
por: Chen, Yu-Syuan, et al.
Publicado: (2022)

Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents
por: Westermann, Claudia, et al.
Publicado: (2021)

Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients
por: Fouad, Magdy, et al.
Publicado: (2021)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents
por: Kuftinec, Gabriela, et al.
Publicado: (2018)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
por: Kwan, Byung Soo, et al.
Publicado: (2021)

Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals
por: Mercan-Stanciu, Adriana, et al.
Publicado: (2022)

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?
por: Lee, Hye Won
Publicado: (2022)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
por: Leal, Cassia, et al.
Publicado: (2023)

Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria
por: Ochi, Hironori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3aol2pmoj50oa2bk79ssd7g0c0